After stopping a PPI, rebound acid hypersecretion can cause new heartburn and reflux symptoms, even in people who had none before.
Original statement
لكنّ المفتاح الذي يفسّر الإدمان الذي يصفه د. ضياء هو دراسة ريمر (Gastroenterology 2009): 120 متطوعاً صحيحاً تماماً، أُعطوا إيزوميبرازول 40 ملغ ثمانية أسابيع. بعد التوقف، 44% منهم ظهرت لديهم حرقة وارتداد لأول مرة في حياتهم، مقابل 15% للغفل. الدواء يخلق المرض الذي يدّعي علاجه. هذا هو الفخّ الذي يحذّر منه: ابدأ نكسيم لشكوى عابرة، فلا تستطيع التوقف.
not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.
Translation
After stopping a PPI, rebound acid hypersecretion can cause new heartburn and reflux symptoms, even in people who had none before.
Origin
- Source status
- Archive editors
- Attribution
- Archive editors (eltayebat.com); not verified as Elawady's own words
- Origin
- https://eltayebat.com/rule/acid-blockers/
- Attribution uncertainty
- Written by the archive operators; study selection is the archive's, not necessarily Elawady's.
- Claimed mechanism
Prolonged acid suppression raises gastrin and parietal-cell mass; after withdrawal acid output transiently overshoots.
- Claimed health effect
New or worse acid-related symptoms after stopping.
- Population concerned
PPI users after withdrawal (shown in healthy volunteers).
- Geographic restriction by Elawady
none found
Diverging source versions
الحموضة أو ارتجاع المرئ والقولون العصبي مرضين في الجهاز الهضمي ممكن نتخلص منهم تماما لو بطلنا عادات سيئة كتير بنعملها في أكلنا لو شوية تحسين في التغذية بتاعتنا هتختفي كل الاعراض دي الحموضة العيانين بيشتكوا منها ويروحوا يتعلقوا منها بأدوية بتقلل الحموضة زي الرنتي دي [00:29] زي الرانيتيدين والكنترولات وبعد شوية يكتشفوا ان عندهم جرثوم حلزونية يااخدوا لي لها علاج لا الجرثومة بتخف ولا الارتجاع بيقل مجر ما يوقف الدوااء النهارده الارتجاع بيزيد
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- علاج الحموضة فى خطوة واحدة بس .. ماحدش فكر فيها قبل كده (Open source)
- Published
- 12 March 2021
- Timestamp
- not available (transcript has no timings)
حمض المعدة ليس عدوّاً يجب قمعه، بل أداة أساسية للهضم وقتل الميكروبات وامتصاص الحديد وفيتامين ب12 والكالسيوم والمغنيزيوم. تثبيطه لفترات طويلة بـ PPIs (أوميبرازول، نكسيم، كونترلوك) أو مثبطات H2 ينقلب على الجسم: مرض كلوي مزمن، فرط نمو بكتيري، عدوى مطثية عسيرة، التهاب رئوي، نقص B12 والمغنيزيوم، كسور ورك، تغيّر الميكروبيوم، وزيادة الوفيات. والأخطر أنّ الجسم يدمن الدواء عبر فرط الإفراز الارتدادي بعد الإيقاف، فيتحوّل الاستخدام القصير إلى اعتماد مزمن.
- Source status
- Archive editors
- Attribution
- Archive editors (eltayebat.com)
- Origin
- https://eltayebat.com/rule/acid-blockers/
Scientific assessment
Mostly true – Correct at its core, but with limitations or minor inaccuracies.
Certainty of evidence: moderate – Further research may still affect the assessment.
1. What was claimed?
Stopping PPIs causes rebound acid symptoms, even in healthy people.
2. What is demonstrably correct?
Correct. In Reimer 2009, 44% (26/59) of healthy volunteers who stopped 8 weeks of esomeprazole reported at least one relevant acid-related symptom in weeks 9–12 versus 15% (9/59) on placebo. AGA 2022 advises warning patients about transient rebound symptoms.
3. What is wrong or exaggerated?
The narrative's phrase 'for the first time in their lives' and the conclusion that the drug 'manufactures the disease' overstate a transient, mostly mild effect; weekly proportions fell to 21% (vs 2%) by week 12.
4. What remains unclear?
The clinical importance of rebound in patients with real reflux disease is unclear (studies were methodologically weak).
5. Which studies support it?
A-PPI-14; Lødrup 2013 (I-PPI-06); AGA 2022 BPA 8 (I-PPI-04).
6. Which studies contradict it?
Lødrup 2013: three studies in reflux patients found no sign of symptomatic rebound (but with methodological weaknesses).
7. What applies to Germany and Europe?
PPIs are among the most widely prescribed drugs in Germany and Europe; several (e.g. pantoprazole, omeprazole) are sold over the counter in small packs for short-term use. European data (Stockholm, UK GPRD/CPRD, Rotterdam) are among the cited cohorts, so the observational findings apply to European users with the same confounding limits.
8. What is known about Egypt?
Elawady describes PPIs (Controloc, Nexium) as widely used and sold without prescription in Egypt. No Egypt-specific outcome data were reviewed. The biology and trial results are not expected to differ by country; H. pylori infection, which is common in many countries, is an additional reason why acid-suppression and eradication therapy are prescribed.
9. What practical conclusion is appropriate?
When a PPI is stopped, transient symptoms are expected and do not by themselves prove that the drug is needed; tapering or on-demand use can help (AGA 2022, Farrell 2017).
Assessment details
- Rationale for certainty of evidence
One well-conducted double-blind RCT in 120 healthy volunteers plus a second volunteer study (systematic review: 44% symptoms up to 4 weeks after withdrawal); evidence in reflux patients is weak and inconsistent; AGA 2022 accepts transient rebound symptoms.
- Source quality
RCT correctly cited by the archive.
- Regional transferability
High.
- Individual exceptions
Symptoms are usually mild to moderate and transient.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 26 October 2026 provisional
Scientific evidence in detail
Scientifically well supported – The claim agrees with consistent, high-quality evidence.
Research question: After stopping a PPI, can rebound acid hypersecretion cause new heartburn/reflux symptoms, even in people who had none before?
Research question in detail (PICO)
- Population
- Healthy volunteers and PPI users
- Intervention or exposure
- Stopping a PPI after weeks of use
- Comparison
- Stopping placebo
- Geographic scope
- universal pharmacology
- Outcomes
- New acid-related/dyspeptic symptoms after withdrawal
- Duration
Study results as reported by the authors. Our assessment follows below.
What speaks for the claim?
Stopping a PPI can cause rebound heartburn
Reimer C et al.. Gastroenterology 2009 · PMID 19362552 · DOI 10.1053/j.gastro.2009.03.058 Randomised controlled trialabstract checkedDouble-blind RCT (n=118 healthy): symptoms after stopping 8 weeks esomeprazole.
- Actual result
- 44% vs 15%
- Methodological quality
- high (RCT)
- Relevance
- direct
- Limitations
- Healthy volunteers
Stopping an acid blocker caused short-lived indigestion in healthy people
Niklasson A et al.. Am J Gastroenterol 2010 · PMID 20332770 · DOI 10.1038/ajg.2010.81 Randomised controlled trialabstract checkednewly addedDouble-blind RCT (n=48 healthy): dyspepsia after stopping 4 weeks pantoprazole, correlated with gastrin.
- Actual result
- 44% vs 9%; gone by week 3
- Methodological quality
- high (small RCT)
- Relevance
- direct
- Limitations
- Small
What speaks against the claim?
ACG 2022 reflux guideline
Katz PO et al.. Am J Gastroenterol 2022 · PMID 34807007 · DOI 10.14309/ajg.0000000000001538 Guideline / position statementfull text checkedACG 2022: rebound shown in healthy controls but strong evidence for symptom increase after abrupt withdrawal in patients is lacking.
- Actual result
- Guideline text
- Methodological quality
- guideline
- Relevance
- limits generalisation to patients
- Limitations
- Expert judgement
What does the overall evidence say?
Editorial assessment based on the studies above – not itself a study result.
Which position is better supported?
Rebound symptoms after stopping PPIs are real in previously asymptomatic people and usually transient.
Why some studies weigh more
Two independent double-blind RCTs agree.
Is a causal relationship established? Yes, established Randomised placebo-controlled replication with biological gradient (gastrin).
Remaining uncertainty
Relevance in patients with GERD.
Justified conclusion
Correct.
Does this depend on the country?
- General biological effects
- Pharmacology of PPIs is the same in Egypt and Europe.
- Eating habits
- Not decisive.
- Origin of the food
- Not relevant.
- Contaminants
- Not relevant (except ranitidine NDMA impurities, C-PPI-08).
- National production conditions
- Generic products are used in both regions; no evidence of different pharmacological effects.
- Legal rules
- PPIs are partly available without prescription in Egypt and (small packs, short-term) in the EU; prescribing practices differ.
- Actual monitoring data
- No Egyptian outcome data identified; one Egypt/Iraq pharmacist survey (I-PPI-120).
A regional difference that changes the conclusion is not supported by robust data.
Statistical re-check
- RR, RD, NNH – RR 5.06 (1.25-20.4); RD 0.35; NNH about 3 recalculated
- RR, RD, NNH – RR 2.89 (1.48-5.63); RD 0.29; NNH about 3.5 recalculated
Certainty of the overall evidence (GRADE, simplified)
- Main outcome
- Transient symptoms after PPI withdrawal in healthy people
- Starting level
- high (randomised trials)
- Reasons for downgrading
- imprecision (small trials)
- Result
- moderate
Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.
Clinical guidelines and official statements checked
- AGA (American Gastroenterological Association): AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review (Targownik LE et al., Gastroenterology 2022; I-PPI-04) (2022) · Original publication
Best Practice Advice read verbatim in the PubMed record: regular review and documentation of the indication (BPA 1); trial of de-prescribing for all without a definitive indication (BPA 2); complicated GERD (severe erosive oesophagitis, oesophageal ulcer, peptic stricture) generally not for discontinuation (BPA 4); Barrett's oesophagus, eosinophilic oesophagitis, idiopathic pulmonary fibrosis generally not for de-prescribing (BPA 5); assess upper GI bleeding risk first and do not de-prescribe in high-risk patients (BPA 6-7); warn about transient rebound symptoms (BPA 8); tapering or abrupt stop both possible (BPA 9); decide on indication, not on fear of PPI-associated adverse events (BPA 10). The publisher page could not be fetched (HTTP 403). - ACG (American College of Gastroenterology): ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease (Katz PO et al. 2022; I-PPI-10) (2022) · Original publication
Full text read: weight loss recommended for overweight/obese patients (strong, moderate evidence); avoid meals within 2-3 h of bedtime, avoid tobacco, avoid 'trigger foods', elevate head of bed for nocturnal symptoms (conditional, low evidence); Table 3 rates 'avoid carbonated beverages' as moderate evidence and recommendable; PPIs over H2RAs for healing erosive oesophagitis (strong, high evidence); attempt to discontinue PPIs in patients without erosive oesophagitis or Barrett's whose symptoms resolved (conditional, low); maintenance PPI indefinitely or surgery for LA grade C/D oesophagitis (strong, moderate); endoscopy first for dysphagia or alarm symptoms (weight loss, GI bleeding); rebound shown in healthy controls but strong evidence for symptom increase after abrupt withdrawal in patients is lacking.
Search strategy
Documented literature searches for this review (search strings in the original database syntax).
| Database | Date | Search | Looking for | Hits | Included |
|---|---|---|---|---|---|
| Europe PMC | 26 October 2026 | ("rebound acid hypersecretion" OR "rebound" ) AND ("proton pump inhibitor" OR esomeprazole OR pantoprazole OR omeprazole) AND (withdrawal OR discontinuation) AND (randomized OR randomised OR placebo) | supporting evidence | 617 | |
| Europe PMC | 26 October 2026 | TITLE:(dyspeptic OR "acid-related" OR rebound OR "acid hypersecretion") AND TITLE:(discontinuation OR withdrawal OR cessation OR stopping) AND (proton OR esomeprazole OR pantoprazole OR omeprazole OR lansoprazole) | both directions | 15 | |
| PubMed (E-utilities esearch) | 26 October 2026 | (proton pump inhibitors[mh]) AND (deprescriptions[mh] OR discontinu*[ti]) AND (randomized controlled trial[pt] OR systematic review[pt]) | both directions | 17 | |
| Web (curl/WebFetch of guideline page) | 26 October 2026 | https://pmc.ncbi.nlm.nih.gov/articles/PMC8754510/ (ACG 2022 GERD guideline full text; Europe PMC fullTextXML returned HTTP 500) | guidelines | 1 | |
| PubMed efetch (record of PMID 35183361) | 26 October 2026 | efetch id=35183361 (AGA 2022 de-prescribing BPA statements); publisher page attempted via WebFetch returned HTTP 403 | guidelines | 1 |
Open questions
Rebound size after years of use.
How deeply was this checked?
6 linked studies: 1 checked in full text (0 of them with a structured risk-of-bias assessment), 5 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.
Last scientific review: 26 October 2026
History of the verdict
- 25 October 2026 · Phase 1 · Initial assessment: Mostly true (moderate)
- 26 October 2026 · Phase 4 (systematic evidence review) · Re-examined with extended evidence; verdict unchanged: Mostly true (moderate)
Independent replication strengthens the claim but trials are small and in healthy volunteers; verdict and certainty unchanged.
New sources: I-PPI-104 I-PPI-105
In plain language
If you take a strong acid blocker for some weeks and then stop, the stomach can make more acid than usual for a while. A good trial in healthy volunteers showed that almost half had heartburn-type symptoms in the following weeks, compared with 15% on placebo. These symptoms are usually mild and pass.
Studies on this claim
Studies supporting the claim (5)
-
Stopping a PPI can cause rebound heartburn
Reimer C et al.. Gastroenterology 2009 · PMID 19362552 · DOI 10.1053/j.gastro.2009.03.058Randomised controlled trialcited by the Tayebat archiveabstract checked★ key studyAfter stopping esomeprazole, 44% of healthy volunteers had acid symptoms vs 15% on placebo.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Rebound symptoms after PPI.
- How was the study done?
Double-blind RCT.
- How many people, animals or samples were studied?
120 healthy adults.
- What was actually found?
More acid symptoms after withdrawal.
- How large was the observed effect?
44% vs 15%.
- What do the results mean in everyday life?
Expect temporary symptoms when stopping.
- What are the study's limitations?
Short follow-up; mild symptoms.
- What does it say about Elawady's specific claim?
Supports rebound, not 'addiction'.
- Do the results apply to Germany and Europe?
Applicable.
- What can explicitly not be concluded from this study?
Lifelong dependence.
-
Rebound symptoms after stopping PPIs – review
Lødrup AB et al.. Scand J Gastroenterol 2013 · PMID 23311977 · DOI 10.3109/00365521.2012.746395Systematic reviewindependent cross-checkabstract checked★ key studyVolunteers often get mild symptoms for up to 4 weeks; patients' studies show no clear rebound.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
RAHS symptoms.
- How was the study done?
Systematic review.
- How many people, animals or samples were studied?
5 studies.
- What was actually found?
Mild transient symptoms in volunteers.
- How large was the observed effect?
44%.
- What do the results mean in everyday life?
Temporary symptoms.
- What are the study's limitations?
Few studies.
- What does it say about Elawady's specific claim?
Supports rebound, limits 'addiction'.
- Do the results apply to Germany and Europe?
Applicable.
- What can explicitly not be concluded from this study?
Effect in patients.
-
How to stop PPIs safely (AGA 2022)
Targownik LE et al.. Gastroenterology 2022 · PMID 35183361 · DOI 10.1053/j.gastro.2021.12.247Guideline / position statementindependent cross-checkabstract checked★ key studyStop PPIs without a definite indication; keep them in Barrett's, severe oesophagitis and high bleeding risk; expect temporary rebound.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
De-prescribing guidance.
- How was the study done?
Expert review.
- What was actually found?
10 statements.
- What do the results mean in everyday life?
Many people can stop; some must not.
- What are the study's limitations?
Expert opinion.
- What does it say about Elawady's specific claim?
Supports overuse claim; contradicts universal ban and 'cannot stop'.
- Do the results apply to Germany and Europe?
Applicable.
-
Stopping an acid blocker caused short-lived indigestion in healthy people
Niklasson A et al.. Am J Gastroenterol 2010 · PMID 20332770 · DOI 10.1038/ajg.2010.81Randomised controlled trialindependent cross-checkabstract checked★ key studyAfter 4 weeks of pantoprazole, 44% of healthy volunteers developed indigestion when they stopped, compared with 9% after placebo; it faded within 3 weeks.
44% vs 9% new dyspepsia after stopping pantoprazole
Does the study support the specific claim? Yes · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Test for rebound after stopping a PPI.
- How was the study done?
Double-blind RCT.
- How many people, animals or samples were studied?
48 healthy volunteers.
- What was actually found?
44% vs 9% developed indigestion; gone by week 3.
- How large was the observed effect?
RR about 5; NNH about 3.
- What do the results mean in everyday life?
Expect a few weeks of symptoms after stopping; it does not mean you need the drug.
- What are the study's limitations?
Small; short treatment.
- What does it say about Elawady's specific claim?
Supports rebound claim; limits 'dependence' claim.
- Do the results apply to Germany and Europe?
Applicable.
- What can explicitly not be concluded from this study?
Cannot show permanent dependence.
-
Are acid blockers addictive?
Namikawa K et al.. Int J Mol Sci 2024 · PMID 38791497 · DOI 10.3390/ijms25105459Narrative reviewindependent cross-checkabstract checkedStopping PPIs can cause a temporary acid surge that people mistake for their old illness; warning patients helps them stop.
40-50% of healthy volunteers symptomatic after withdrawal
Does the study support the specific claim? Partly · Methodological quality: low · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Review rebound after PPI withdrawal.
- How was the study done?
Narrative review.
- How many people, animals or samples were studied?
Published studies.
- What was actually found?
Rebound is well established; may cause unnecessary restarts.
- How large was the observed effect?
40-50% symptomatic in volunteers.
- What do the results mean in everyday life?
Knowing about rebound makes stopping easier.
- What are the study's limitations?
Not systematic.
- What does it say about Elawady's specific claim?
Partly supports the 'trap' idea but not 'cannot stop'.
- Do the results apply to Germany and Europe?
Applicable.
- What can explicitly not be concluded from this study?
Cannot quantify long-term dependence.
No study in this group is marked as key.
Studies contradicting or limiting the claim (1)
-
ACG 2022 reflux guideline
Katz PO et al.. Am J Gastroenterol 2022 · PMID 34807007 · DOI 10.14309/ajg.0000000000001538Guideline / position statementindependent cross-checkfull text checked★ key studyWeight loss, avoiding late meals and trigger foods help; PPIs are best for erosive oesophagitis.
Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
GERD management.
- How was the study done?
Guideline.
- What was actually found?
Lifestyle + PPI recommendations.
- What do the results mean in everyday life?
Diet helps; drugs needed for erosive disease.
- What are the study's limitations?
Low evidence for some lifestyle advice.
- What does it say about Elawady's specific claim?
Mixed for diet claims; contradicts ban.
- Do the results apply to Germany and Europe?
Applicable.
No study in this group is marked as key.
Studies with mixed or unclear results (0)
No studies in this group.
Regional context
Germany / EU
PPIs are among the most widely prescribed drugs in Germany and Europe; several (e.g. pantoprazole, omeprazole) are sold over the counter in small packs for short-term use. European data (Stockholm, UK GPRD/CPRD, Rotterdam) are among the cited cohorts, so the observational findings apply to European users with the same confounding limits.
Egypt
Elawady describes PPIs (Controloc, Nexium) as widely used and sold without prescription in Egypt. No Egypt-specific outcome data were reviewed. The biology and trial results are not expected to differ by country; H. pylori infection, which is common in many countries, is an additional reason why acid-suppression and eradication therapy are prescribed.
What applies in my country?
General scientific assessment
Mostly true Correct: rebound acid symptoms after stopping PPIs are real but usually mild and temporary.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy.. Reimer C et al.. Gastroenterology 2009 · PMID 19362552 · DOI 10.1053/j.gastro.2009.03.058
- Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment.. Lødrup AB et al.. Scand J Gastroenterol 2013 · PMID 23311977 · DOI 10.3109/00365521.2012.746395
- AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review.. Targownik LE et al.. Gastroenterology 2022 · PMID 35183361 · DOI 10.1053/j.gastro.2021.12.247
- Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial.. Niklasson A et al.. Am J Gastroenterol 2010 · PMID 20332770 · DOI 10.1038/ajg.2010.81
- Rebound Acid Hypersecretion after Withdrawal of Long-Term Proton Pump Inhibitor (PPI) Treatment-Are PPIs Addictive?. Namikawa K et al.. Int J Mol Sci 2024 · PMID 38791497 · DOI 10.3390/ijms25105459
- ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.. Katz PO et al.. Am J Gastroenterol 2022 · PMID 34807007 · DOI 10.14309/ajg.0000000000001538